Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reviews

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2021;27(2):221-235. Published online December 3, 2020

Web of Science 26 Crossref 29

DOI: https://doi.org/10.3350/cmh.2020.0239

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects

Takuji Torimura, Hideki Iwamoto

Clin Mol Hepatol. 2021;27(2):236-245. Published online December 3, 2020

Web of Science 40 Crossref 38

DOI: https://doi.org/10.3350/cmh.2020.0204

Current and future strategies for the treatment of chronic hepatitis C

Omar Alshuwaykh, Paul Y. Kwo

Clin Mol Hepatol. 2021;27(2):246-256. Published online December 3, 2020

Web of Science 12 Crossref 13

DOI: https://doi.org/10.3350/cmh.2020.0230

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee

Clin Mol Hepatol. 2021;27(2):257-269. Published online March 22, 2021

Web of Science 62 Crossref 62

DOI: https://doi.org/10.3350/cmh.2021.0067

Editorials

A need for patient-centered care in managing patients with liver cirrhosis

Eileen L. Yoon

Clin Mol Hepatol. 2021;27(2):270-272. Published online January 27, 2021

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2021.0001

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2021;27(2):273-277. Published online February 1, 2021

Web of Science 6 Crossref 6

DOI: https://doi.org/10.3350/cmh.2021.0019

Biopsy or cytology for diagnosing hepatic focal lesions?

Haeryoung Kim

Clin Mol Hepatol. 2021;27(2):278-280. Published online March 4, 2021

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2021.0031

Another oral antiviral treatment, but still far away from hepatitis B virus cure

Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(2):281-282. Published online March 10, 2021

Web of Science 5 Crossref 5

DOI: https://doi.org/10.3350/cmh.2021.0072

Original Articles

Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study

Suk-Yong Jang, Woo Sun Rou, Seok Hyun Kim, Byung Seok Lee, Hyuk Soo Eun

Clin Mol Hepatol. 2021;27(2):283-294. Published online December 3, 2020

Web of Science 7 Crossref 9

DOI: https://doi.org/10.3350/cmh.2020.0227

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clin Mol Hepatol. 2021;27(2):295-304. Published online December 3, 2020

Web of Science 16 Crossref 19

DOI: https://doi.org/10.3350/cmh.2020.0216

Direct comparison of biopsy techniques for hepatic malignancies

Shang-Chin Huang, Ja-Der Liang, Shih-Jer Hsu, Tzu-Chan Hong, Hung-Chih Yang, Jia-Horng Kao

Clin Mol Hepatol. 2021;27(2):305-312. Published online December 3, 2020

Web of Science 10 Crossref 11

DOI: https://doi.org/10.3350/cmh.2020.0301

Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma

Ching-Chih Lin, Ta-Wei Liu, Ming-Lun Yeh, Yi-Shan Tsai, Pei-Chien Tsai, Chung-Feng Huang, Jee-Fu Huang, Wan-Long Chuang, Chia-Yen Dai, Ming-Lung Yu

Clin Mol Hepatol. 2021;27(2):313-328. Published online December 14, 2020

Web of Science 9 Crossref 7

DOI: https://doi.org/10.3350/cmh.2020.0247

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding

Clin Mol Hepatol. 2021;27(2):329-345. Published online January 20, 2021

Web of Science 12 Crossref 16

DOI: https://doi.org/10.3350/cmh.2020.0261

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial

Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Jin Mo Yang, Kyun-Hwan Kim, Kwang-Hyub Han, Soon Ho Um

Clin Mol Hepatol. 2021;27(2):346-359. Published online January 25, 2021

Web of Science 11 Crossref 9

DOI: https://doi.org/10.3350/cmh.2020.0307

Letter to the Editor

Clinical and serological prognostic markers in primary biliary cholangitis

Markus Wilhelmi

Clin Mol Hepatol. 2021;27(2):360-361. Published online March 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0088

Viewed By 5398	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5362	MAFLD: How is it different from NAFLD?
Viewed By 5246	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3925	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3902	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Previous issues